Health & Medicine - Posted by Leslie Ridgeway-USC on Friday, February 8, 2013 13:58 - 0 Comments
Birth control tied to diabetes risk in obese women
USC (US) — Obese women of reproductive age who use an under-the-skin contraceptive that contains the hormone progestin have a slightly increased risk of developing type 2 diabetes.
The findings, published in the journal Contraception, suggest that long-acting reversible contraception (LARC) appears to be safe for use by such women but needs further investigation.
“Contraceptive studies often only look at normal-weight women,” says Penina Segall-Gutierrez, assistant professor of clinical obstetrics and gynecology and family medicine at the Keck School of Medicine at the University of Southern California.
Straight from the Source
“Studies such as this are necessary because, today, one-third of women in the US are overweight and one-third are obese. All women, including overweight and obese women, need to have access to safe and effective contraception.”
Obese women are at increased risk for pregnancy-related complications and are sometimes warned by their doctors not to use contraceptives containing estrogen, such as the pill, patch, and vaginal ring.
“[Those choices] raise the risk for blood clots,” Segall-Gutierrez says. “So they need other, viable alternatives. The implanted LARC devices last three to 10 years, are easily reversible, and women don’t have to remember to do anything with them, in contrast to the birth-control pill.”
The six-month study observed the metabolic markers in three groups of obese women: a control group using non-hormonal birth control methods, including condoms, the copper IUD, and female or male sterilization; a second group with a progestin-releasing LARC device implanted in the uterus (IUD); and a third group with a progestin-releasing LARC device implanted under the skin.
“All three methods were found to be safe and effective, and they did not create changes in blood pressure, weight, or cholesterol,” Segall-Gutierrez says. “However, there was a 10 percent increase in fasting blood-glucose levels among the skin implant users, compared to a 5 percent increase among the IUD users and a 2 percent decrease among those using non-hormonal methods.
“The effects on sensitivity to insulin showed a similar trend. It is unknown if these effects would continue if the devices were used and studied for a longer period of time.”
Segall-Gutierrez has studied the metabolic effects of other birth-control methods as well. In 2012, they reported findings that obese women receiving a progestin birth-control shot every three months may be at increased risk for developing type 2 diabetes.
“Overall, we’re finding that methods such as the progestin injection and the progestin skin implant, which both have higher circulating progestin, may have an increased risk for metabolic changes compared to methods like the IUD, which only has a local effect—in the uterus,” she says.
Progestin-releasing IUD has other benefits. It is approved by the US Food and Drug Administration for treatment of heavy menstrual bleeding, which often affects obese women. The IUD also protects against endometrial cancer, which disproportionately affects obese women.
“Choosing a birth-control method requires consideration of many factors, including the patient’s lifestyle and willingness to use the method, desire for future fertility, and risk for a host of diseases—diabetes and endometrial cancer being two of them for obese women,” Segall-Gutierrez says.
“We would like to expand our most recent study by looking at more participants over a longer period of time to see if the metabolic effects we observed in the progestin-releasing implants persist or are only temporary.”